long intergenic non-protein coding RNA 1210Genealiases: []
Q-omics provides the consensus-scored LINC01210 profile across patient tissues and cancer cell-line models. LINC01210 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, LINC01210 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, LINC01210 RNA expression shows 5,744 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, COAD, and STAD as cancer lineages where LINC01210 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01210 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01210 survival associations across molecular data types. LINC01210 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01210 RNA expression–survival associations across cancer types. High LINC01210 expression shows unfavorable associations in UCS, ACC, CESC and SKCM, but favorable associations in STAD and OV. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for LINC01210 RNA expression.
This table summarizes LINC01210 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01210. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01210 shows higher tumor expression in COAD, STAD, PRAD and LUSC. The COAD box plot shows higher LINC01210 RNA expression in tumor versus normal tissue (log2 FC = +0.092, t-test p = .002).
This table shows molecular features associated with LINC01210 in patient tissues and cancer cell lines. In patient samples, LINC01210 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
